DOCSLIB.ORG

Voting, April-June 2012

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Voting, April-June 2012 Schroders Voting, April-June 2012 Schroders is required to publish records of voting in order to achieve compliance with the UK Stewardship Code. According, voting in accordance with our house policy is set out on the following pages. Vote Summary Report Report was run from: 4/1/12 to 6/30/12 Eurasian Natural Resources Corporation plc Meeting Date: 02-Apr-12 Meeting Type: Special Proposal Vote Number Proposal Instruction This Adjourned General Meeting Follows the Original General Meeting which was Held on 7 November 2011 1 Approve Acquisition of Shares in Shubarkol Komir Against JSC RMAC 2004-NSP4 PLC, BRACKNELL Meeting Date: 02-Apr-12 Meeting Type: Bondholder Proposal Vote Number Proposal Instruction Meeting of the Holders of the GBP 595,000,000 Class A2 Notes Mortgage Backed Floating Rate Notes due December 2036 1 Authorise Issuer and Trustee to Consent to the Do Not Vote Amendment of Clause 25.1 of the Liquidity Facility Agreement; Sanction Abrogation of the Rights of the Instrumentholders; Discharge Trustee from Any and All Liability RMAC 2005-NSP2 PLC Meeting Date: 02-Apr-12 Meeting Type: Bondholder Vote Summary Report Report was run from: 4/1/12 to 6/30/12 RMAC 2005-NSP2 PLC Proposal Vote Number Proposal Instruction Meeting of the Holders of the GBP 220,000,000 Class A2a Notes Mortgage Backed Floating Rate Notes Due September 2037 1 Authorise Issuer and Trustee to Consent to the Do Not Vote Amendment of Clause 25.1 of the Liquidity Facility Agreement; Sanction Abrogation of the Rights of the Instrumentholders; Discharge Trustee from Any and All Liability RMAC SECURITIES NO.1 PLC Meeting Date: 02-Apr-12 Meeting Type: Bondholder Proposal Vote Number Proposal Instruction Meeting of the Holders of the GBP 385,000,000 Class A2a Notes Mortgage Backed Floating Rate Notes Due June 2044 1 Authorise Series Note Trustee to Amend Clause 24.1 For and Waive Any Breach of Terms of the Series Liquidity Facility Agreement; Sanction Variation of Noteholders' Rights; Discharge Series Note Trustee from Any and All Liability London Stock Exchange Group plc Meeting Date: 03-Apr-12 Meeting Type: Special Vote Summary Report Report was run from: 4/1/12 to 6/30/12 London Stock Exchange Group plc Proposal Vote Number Proposal Instruction 1 Approve Acquisition of a Majority Interest in For LCH.Clearnet Group Limited NetPlay TV plc Meeting Date: 03-Apr-12 Meeting Type: Special Proposal Vote Number Proposal Instruction 1 Approve Reduction of Share Premium Account and For Cancellation of Issued Deferred Shares Telecity Group plc Meeting Date: 04-Apr-12 Meeting Type: Annual Proposal Vote Number Proposal Instruction 1 Accept Financial Statements and Statutory Reports For 2 Approve Remuneration Report For 3 Re-elect John Hughes as Director For 4 Re-elect Michael Tobin as Director For 5 Re-elect Brian McArthur-Muscroft as Director For 6 Re-elect Simon Batey as Director For 7 Re-elect John O'Reilly as Director For Vote Summary Report Report was run from: 4/1/12 to 6/30/12 Telecity Group plc Proposal Vote Number Proposal Instruction 8 Elect Maurizio Carli as Director For 9 Elect Sahar Elhabashi as Director For 10 Reappoint PricewaterhouseCoopers LLP as Auditors For 11 Authorise Board to Fix Remuneration of Auditors For 12 Authorise Issue of Equity with Pre-emptive Rights For 13 Authorise Issue of Equity without Pre-emptive For Rights 14 Authorise Market Purchase For 15 Approve Long-Term Incentive Plan 2012 For 16 Authorise the Company to Call EGM with Two For Weeks' Notice Liontrust Asset Management plc Meeting Date: 05-Apr-12 Meeting Type: Special Proposal Vote Number Proposal Instruction 1 Approve Acquisition of Walker Crips Asset Managers For Limited 2 Authorise Issue of Equity with Pre-emptive Rights in For Connection with the Acquistion 3 Authorise Issue of Equity without Pre-emptive For Rights in Connection with the Acquistion 4 Amend Articles of Association For 5 Adopt New Articles of Association For Vote Summary Report Report was run from: 4/1/12 to 6/30/12 All Leisure Group plc Meeting Date: 11-Apr-12 Meeting Type: Annual Proposal Vote Number Proposal Instruction 1 Accept Financial Statements and Statutory Reports For 2 Approve Final Dividend For 3 Re-elect Rob Bryant as Director For 4 Re-elect Philip Ovenden as Director For 5 Reappoint Deloitte LLP as Auditors For 6 Authorise Board to Fix Remuneration of Auditors For 7 Authorise Issue of Equity with Pre-emptive Rights For 8 Authorise Issue of Equity without Pre-emptive For Rights 9 Authorise Market Purchase For Carnival plc Meeting Date: 11-Apr-12 Meeting Type: Annual Proposal Vote Number Proposal Instruction 1 Re-elect Micky Arison as Director of Carnival For Corporation and as a Director of Carnival plc 2 Re-elect Sir Jonathon Band as Director of Carnival For Corporation and as a Director of Carnival plc 3 Re-elect Robert Dickinson as Director of Carnival For Corporation and as a Director of Carnival plc 4 Re-elect Arnold Donald as Director of Carnival For Corporation and as a Director of Carnival plc Vote Summary Report Report was run from: 4/1/12 to 6/30/12 Carnival plc Proposal Vote Number Proposal Instruction 5 Re-elect Pier Foschi as Director of Carnival For Corporation and as a Director of Carnival plc 6 Re-elect Howard Frank as Director of Carnival For Corporation and as a Director of Carnival plc 7 Re-elect Richard Glasier as Director of Carnival For Corporation and as a Director of Carnival plc 8 Elect Debra Kelly-Ennis as Director of Carnival For Corporation and as a Director of Carnival plc 9 Re-elect Modesto Maidique as Director of Carnival For Corporation and as a Director of Carnival plc 10 Re-elect Sir John Parker as Director of Carnival For Corporation and as a Director of Carnival plc 11 Re-elect Peter Ratcliffe as Director of Carnival For Corporation and as a Director of Carnival plc 12 Re-elect Stuart Subotnick as Director of Carnival For Corporation and as a Director of Carnival plc 13 Re-elect Laura Weil as Director of Carnival For Corporation and as a Director of Carnival plc 14 Re-elect Randall Weisenburger as Director of For Carnival Corporation and as a Director of Carnival plc 15 Reappoint PricewaterhouseCoopers LLP as Auditors For of Carnival plc; Ratify the Selection of PricewaterhouseCoopers LLP as Registered Certified Public Accounting Firm of Carnival Corporation 16 Authorise the Audit Committee of Carnival plc to Fix For Remuneration of Auditors 17 Accept Financial Statements and Statutory Reports For 18 Advisory Vote to Approve Compensation of the For Named Executive Officers 19 Approve Remuneration Report For 20 Authorise Issue of Equity with Pre-emptive Rights For 21 Authorise Issue of Equity without Pre-emptive For Rights 22 Authorise Market Purchase For 23 Report on Political Contributions For Vote Summary Report Report was run from: 4/1/12 to 6/30/12 Melrose plc Meeting Date: 11-Apr-12 Meeting Type: Special Proposal Vote Number Proposal Instruction 1 Approve Sub-Division and Redesignation of Existing For Incentive Shares Into New Ordinary Shares Arising on the Existing Incentive Share Crystallisation; Approve Bonus Issue 2 Amend Articles of Association Re: Incentive Shares For 3 Authorise Issue of Equity with and without For Pre-emptive Rights in Connection with the 2012 Incentive Shares BP plc Meeting Date: 12-Apr-12 Meeting Type: Annual Proposal Vote Number Proposal Instruction 1 Accept Financial Statements and Statutory Reports For 2 Approve Remuneration Report Abstain 3 Re-elect Robert Dudley as Director For 4 Re-elect Iain Conn as Director For 5 Elect Dr Brian Gilvary as Director For 6 Re-elect Dr Byron Grote as Director For 7 Re-elect Paul Anderson as Director For 8 Re-elect Frank Bowman as Director For 9 Re-elect Antony Burgmans as Director For 10 Re-elect Cynthia Carroll as Director For Vote Summary Report Report was run from: 4/1/12 to 6/30/12 BP plc Proposal Vote Number Proposal Instruction 11 Re-elect George David as Director For 12 Re-elect Ian Davis as Director For 13 Elect Dame Ann Dowling as Director For 14 Re-elect Brendan Nelson as Director For 15 Re-elect Phuthuma Nhleko as Director For 16 Elect Andrew Shilston as Director For 17 Re-elect Carl-Henric Svanberg as Director For 18 Reappoint Ernst & Young LLP as Auditors and For Authorise Their Remuneration 19 Authorise Market Purchase For 20 Authorise Issue of Equity with Pre-emptive Rights For 21 Authorise Issue of Equity without Pre-emptive For Rights 22 Authorise the Company to Call EGM with Two For Weeks' Notice Smith & Nephew plc Meeting Date: 12-Apr-12 Meeting Type: Annual Proposal Vote Number Proposal Instruction 1 Accept Financial Statements and Statutory Reports For 2 Approve Remuneration Report For 3 Approve Final Dividend For 4 Re-elect Ian Barlow as Director For 5 Re-elect Genevieve Berger as Director For 6 Re-elect Olivier Bohuon as Director For 7 Re-elect Sir John Buchanan as Director For Vote Summary Report Report was run from: 4/1/12 to 6/30/12 Smith & Nephew plc Proposal Vote Number Proposal Instruction 8 Re-elect Adrian Hennah as Director For 9 Re-elect Dr Pamela Kirby as Director For 10 Re-elect Brian Larcombe as Director For 11 Re-elect Joseph Papa as Director For 12 Elect Ajay Piramal as Director For 13 Re-elect Richard De Schutter as Director For 14 Reappoint Ernst & Young LLP as Auditors For 15 Authorise Board to Fix Remuneration of Auditors For 16 Authorise Issue of Equity with Pre-emptive Rights For 17 Approve Sharesave Plan 2012 For 18 Approve International Sharesave Plan 2012 For 19 Authorise Issue of Equity without Pre-emptive For Rights 20 Authorise Market
Load more

Recommended publications
  • UNITED STATES SECURITIES and EXCHANGE COMMISSION Washington, D.C
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* GENOCEA BIOSCIENCES, INC. (Name of Issuer) Common Stock, Par Value $0.001 (Title of Class of Securities) 372427 10 4 (CUSIP Number) Victoria A. Whyte GlaxoSmithKline plc 980 Great West Road Brentford, Middlesex TW8 9GS England Telephone: +44 (0)208 047 5000 Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) July 30, 2015 (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐ Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule.13d-7 for other parties to whom copies are to be sent. * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
    [Show full text]
  • Corporate Governance
    Strategic report Governance and remuneration Financial statements Investor information Corporate Governance In this section Chairman’s Governance statement 78 The Board 80 Corporate Executive Team 83 Board architecture 85 Board roles and responsibilities 86 Board activity and principal decisions 87 Our purpose, values and culture 90 The Board’s approach to engagement 91 Board performance 94 Board Committee information 96 Our Board Committee reports 97 Section 172 statement 108 Directors’ report 109 GSK Annual Report 2020 77 Chairman’s Governance statement In last year’s Governance statement, I explained that our primary Education and focus on Science objective for 2020 was to ensure there was clarity between the Given the critical importance of strengthening the pipeline, Board and management on GSK’s execution of strategy and its the Board has benefitted from devoting a higher proportion of operational priorities. We have aligned our long-term priorities its time in understanding the science behind our strategy and of Innovation, Performance and Trust powered by culture testing its application. It is important that the Board has a and agreed on the metrics to measure delivery against them. working understanding of the key strategic themes upon The Board’s annual cycle of meetings ensures that all major which our R&D strategy is based. These themes have been components of our strategy are reviewed over the course complemented by Board R&D science thematic deep dives. of the year. Our focus was on the fundamentals of our strategy: human The COVID-19 pandemic impacted and dominated all our genetics, the immune system and AI and ML, as well as to lives for the majority of 2020.
    [Show full text]
  • Governance and Remuneration 2014
    Governance & remuneration reportStrategic In this section Our Board 72 Our Corporate Executive Team 76 Chairman’s letter 78 Corporate governance framework 79 Board report to shareholders Oversight and stewardship in 2014 and future actions 80 remuneration & Governance Leadership and effectiveness 82 Committee reports Audit & Risk 86 Nominations 92 Corporate Responsibility 94 Remuneration report Chairman’s annual statement 96 Annual report on remuneration 97 2014 Remuneration policy report 119 Financial statements Financial Investor information Investor GSK Annual Report 2014 71 Our Board Strategic reportStrategic Diversity Experience International experience Composition Tenure (Non-Executives) % % % % Scientific 19 Global 75 Executive 19 Up to 3 years 39 % % % % Finance 31 USA 100 Non-Executive 81 3-6 years 15 % % % % Industry 50 Europe 94 Male 69 7-9 years 23 % % % EMAP 63 Female 31 Over 9 years 23 Sir Christopher Gent 66 Skills and experience Chairman Sir Christopher has many years of experience of leading global businesses and a track record of delivering outstanding performance Governance & remuneration & Governance Nationality in highly competitive industries. He was appointed Managing Director British of Vodafone plc in 1985 and then became its Chief Executive Officer Appointment date in 1997 until his retirement in 2003. Sir Christopher was also a 1 June 2004 and as Chairman Non-Executive Director of Ferrari SpA and a member of the British on 1 January 2005 Airways International Business Advisory Board. Committee membership External appointments Corporate Responsibility Sir Christopher is a Senior Adviser at Bain & Co. Committee Chairman, Nominations, Remuneration and Finance Sir Philip Hampton 61 Skills and experience Chairman Designate Prior to joining GSK, Sir Philip chaired major FTSE 100 companies including J Sainsbury plc.
    [Show full text]
  • MORPHIC HOLDING, INC. (Name of Issuer)
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 240.13d-2(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3) MORPHIC HOLDING, INC. (Name of Issuer) Common Stock, Par Value $0.0001 (Title of Class of Securities) 61775R 10 5 (CUSIP Number) Victoria A. Whyte GlaxoSmithKline plc 980 Great West Road Brentford, Middlesex TW8 9GS England Telephone: +44 (0)208 047 5000 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) June 23, 2020 (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐ Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent. * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.
    [Show full text]
  • Annual Report of Proxy Voting Record Date
    ANNUAL REPORT OF PROXY VOTING RECORD DATE OF REPORTING PERIOD: JULY 1, 2018 - JUNE 30, 2019 FUND: VANGUARD FTSE 100 UCITS ETF --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ISSUER: 3i Group Plc TICKER: III CUSIP: G88473148 MEETING DATE: 6/27/2019 FOR/AGAINST PROPOSAL: PROPOSED BY VOTED? VOTE CAST MGMT PROPOSAL #1: ACCEPT FINANCIAL STATEMENTS AND ISSUER YES FOR FOR STATUTORY REPORTS PROPOSAL #2: APPROVE REMUNERATION REPORT ISSUER YES FOR FOR PROPOSAL #3: APPROVE FINAL DIVIDEND ISSUER YES FOR FOR PROPOSAL #4: RE-ELECT JONATHAN ASQUITH AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #5: RE-ELECT CAROLINE BANSZKY AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #6: RE-ELECT SIMON BORROWS AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #7: RE-ELECT STEPHEN DAINTITH AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #8: RE-ELECT PETER GROSCH AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #9: RE-ELECT DAVID HUTCHISON AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #10: ELECT COLINE MCCONVILLE AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #11: RE-ELECT SIMON THOMPSON AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #12: RE-ELECT JULIA WILSON AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #13: REAPPOINT ERNST & YOUNG LLP AS AUDITORS ISSUER YES FOR FOR PROPOSAL #14: AUTHORISE BOARD ACTING THROUGH THE ISSUER YES FOR FOR AUDIT AND COMPLIANCE COMMITTEE TO FIX REMUNERATION OF AUDITORS PROPOSAL #15: AUTHORISE EU POLITICAL DONATIONS AND ISSUER YES FOR FOR EXPENDITURE PROPOSAL #16: AUTHORISE ISSUE
    [Show full text]
  • Drug Plan Formulary 2Nd Ed (June 2012).Pdf
    Disclaimer: This guide is offered as an easy reference to the prescription drugs that are supported by the National Prescription Drug Plan. It is by no means intended or to be construed as a directive to physicians to prescribe any of the drugs listed in the Formulary, nor does the National Insurance Board, by making available this guide, assume any responsibility for any treatment regimen or prescription drugs physicians prescribe for their patients with reference to the Formulary. The treatment and prescription process remains the sole purview of physicians in consultation with their patients. NATIONAL PRESCRIPTION DRUG PLAN FORMULARY TABLE OF CONTENTS Foreword ................................................................................. 3 Patient Registration Eligibility.................................................. 8 Completing Registration Forms .................................................. 9 Prescription Processing .......................................................... 10 Key Abbreviations .................................................................. 13 Arthritis .............................................................................. 16 Asthma ............................................................................... 45 Benign Prostatic Hypertrophy (BPH) ..................................... 58 Breast Cancer .................................................................. 63 Diabetes ............................................................................. 69 Epilepsy .............................................................................
    [Show full text]
  • Cusip No. G8807B106 13 D/A2 Page 2 of 7
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* THERAVANCE BIOPHARMA, INC. (Name of Issuer) Ordinary Shares (Title of Class of Securities) G8807B106 (CUSIP Number) Victoria A. Whyte GlaxoSmithKline plc 980 Great West Road Brentford, Middlesex TW8 9GS England Telephone: +44 (0)208 047 5000 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) December 31, 2016 (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐ Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent. * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.
    [Show full text]
  • What Makes a Great Chief Executive? What Makes a Great Chief Executive? Material Consists of 80% Recycled Certification
    Material consists of 80% recycled post-consumer fibre; 10% TCF (totally chlorine free); 10% ECF (elemental chlorine free). FSC certification. NAPM recycled certification. Paper mill accredited with ISO 9001 and ISO 14001 status. All responsibilities to the local environment and manufacturing processes are strictly monitored. The Whitehead Mann Leadership Debate Leadership Mann Whitehead The What makes a great Chief Executive? Chief great a makes What THE WHITEHEAD MANN LEADERSHIP DEBATE LEADERSHIP MANN WHITEHEAD THE What makes a great Chief Executive? Chief agreat What makes Contact Carol Leonard All rights reserved. No part of this publication Whitehead Mann is one of the world’s best-known leadership consultancies may be reproduced, stored in a retrieval system, working with clients to create value through people. As an independent, Whitehead Mann or transmitted in any form or by any means, international partnership, we work as a single team to deliver deep sector Ryder Court electronic, mechanical, photocopying, recording and functional expertise. We are authorities in the areas of leadership; CEO 14 Ryder Street or otherwise, without the express permission concerns; CEO characteristics and career issues at Board and CEO level. London SW1Y 6QB of the copyright owner. Our long track record is built on our contacts, judgement, the quality of our t +44 (0) 207 024 9000 © The Whitehead Mann Partnership LLP board placements and our ability to identify the CEOs of tomorrow. Over 90 f +44 (0) 207 024 9001 of Europe’s top 200 companies and most of the FTSE 100 companies and e [email protected] Fortune 500 organisations have retained Whitehead Mann.
    [Show full text]
  • Corporate Governance
    65 GSK Annual Report 2018 Strategic report Governance and remuneration Financial statements Investor information Corporate Governance In this section Chairman’s Governance statement 66 Our Board 68 Our Corporate Executive Team 71 Leadership and effectiveness 72 Nominations Committee report 77 Accountability 79 Audit & Risk Committee report 79 Relations with stakeholders 89 Engagement activities 89 Science Committee report 91 Corporate Responsibility Committee report 92 Directors’ report 94 66 GSK Annual Report 2018 Chairman’s Governance statement “Our purpose and values have always been a source of great pride for the Board and our employees. It is a powerful force in attracting and retaining talented people who, as individuals, want to be part of a company that contributes meaningfully to society.” Dear Shareholder The Reforms came into effect on 1 January 2019 and seek to drive a I am pleased to present our Corporate Governance report for 2018. number of changes to companies’ underlying corporate governance processes. As a result, the Board has reviewed our existing practices Our governance structure operates from the Board across the Group to identify where they are in line with the Reforms and implemented and we believe it underpins our ability to deliver our strategy and enhancements where appropriate. We will report against the create long-term value and benefit for our shareholders and Reforms in next year’s Annual Report to allow time to embed these stakeholders. new practices in our corporate governance framework and to monitor I can confirm that throughout 2018 the company complied with their operation and effectiveness. the requirements of the Financial Reporting Council’s (FRC) UK However, I wish to highlight in this Report some of the more Corporate Governance Code (current Code) except that Dr Vivienne significant implementation steps which may be of interest to our Cox was unable to attend the company’s 2018 AGM.
    [Show full text]
  • United States Securities and Exchange Commission
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 240.13d-2(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 6*) THERAVANCE BIOPHARMA, INC. (Name of Issuer) Ordinary Shares, par value, $0.00001 (Title of Class of Securities) G8807B106 (CUSIP Number) Victoria A. Whyte GlaxoSmithKline plc 980 Great West Road Brentford, Middlesex TW8 9GS England Telephone: +44 (0)208 047 5000 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) June 17, 2020 (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐ Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent. * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.
    [Show full text]
  • Congress Guide
    INTERNATIONAL CONGRESS 2015 AMSTERDAM netherlands, 26–30 september CONGRESS GUIDE ERSCONGRESS.ORG ERS AMSTERDAM 2015 WelprogrammeCome TO amS outlineterDam ■ WELCOME FROM THE ERS PRESIDENT I am honoured to be hosting the 25th International Congress of the European Respiratory Society in my home city of Amsterdam. Amsterdam is famous for its international trade and it is fitting that the ERS Congress is held in a city that has reaped the benefits from an international outlook. It is imperative that we, as respiratory professionals, mirror this approach and work together as an international network to achieve our goal of promoting lung health and combating lung diseases. The scientific and educational programme promises to deliver a wealth of new material from all sections of respiratory health and disease. The Chairs of the Scientific and Education Councils, together with all the ERS officers, work on the programme throughout the year to ensure it delivers the very best results from the latest Professor Elisabeth Bel research, meeting the needs of respiratory professionals ERS PRESIDENT in all disciplines. This year we have taken the landmark decision to provide the congress scientific and educational programme in a digital format only. With the growth in digital platforms over the last ten years, there is no better time to provide our delegates with all the materials and tools needed in a digital format. Instead of a printed copy, the programme will be available on the Congress website where users can easily browse all the sessions, build their own personal itinerary, and download and print abstracts of interest. All these features will also be available on the Congress App, which is free to download and will be available from August.
    [Show full text]
  • Engagement, Screening and Voting Report 2018
    Engagement, Screening and Voting Report 2018 Carlota Garcia-Manas and Sheila Stefani Responsible Investment Team INTRODUCTION Contents Introduction .............................................................................................................................. 3 Engagement ............................................................................................................................. 5 Screening ............................................................................................................................... 12 Voting: Overview ..................................................................................................................... 14 Voting: Management Resolutions (UK) .................................................................................... 16 Overview ............................................................................................................................ 16 Remuneration (UK) ............................................................................................................. 17 Directors (UK) ..................................................................................................................... 18 Voting: Management Resolutions (Global) ............................................................................... 20 Overview ............................................................................................................................ 20 Remuneration (Global) .......................................................................................................
    [Show full text]